TNFRSF17 and AL amyloidosis: CD19-targeted CAR-T has achieved unprecedented clinical response in leukemia and lymphoma, and now B-cell maturation antigen (BCMA)-targeted CAR-T is yielding remarkable results in patients with multiple myeloma (6, 7).